3billion (CEO Changwon Geum), an artificial intelligence (AI)-based rare disease genetic diagnosis company, announced on the 25th that it has signed a memorandum of understanding (MOU) with the Center for Molecular Medicine (CMM), a genetic medical institution in Kazakhstan, to expand rare disease genetic diagnosis services.
Since its establishment in 2003, CMM has operated the largest genetic counseling and diagnostics network in Kazakhstan, playing a key role in the local genetic medicine sector. Kazakhstan is experiencing a rapidly growing demand for rare disease diagnostics within Central Asia, and 3billion has confirmed its market growth potential, with local sales increasing 233% year-on-year as of the first half of 2025.
Through this agreement, the two parties plan to collaborate on improving diagnostic accuracy and efficiency by combining whole-exome (WES) and whole-genome (WGS) testing technologies based on next-generation sequencing (NGS) with AI-powered genetic variant interpretation technology. 3billion expects that by applying its AI-based genetic interpretation technology to CMM's diagnostic infrastructure, it will be able to strengthen access to precision medicine for local patients.
In addition, 3billion has been officially invited to the annual conference of the Association of Medical Genetics of Kazakhstan (AMGK), hosted by CMM in Kazakhstan from September 23rd to 26th, where it will present clinical applications of its genetic testing services. Through this conference, 3billion is exploring opportunities to expand collaboration across Central Asia, including Kazakhstan.
“Kazakhstan is one of the major countries where demand for rare disease diagnosis is rapidly increasing,” said Lee Sook-jin, Chief Business Officer of 3billion. “This collaboration will provide AI-based precision diagnosis services locally and serve as an opportunity to expand into the Central Asian market in the future.”
- See more related articles
You must be logged in to post a comment.